Treatments Outcomes of Refractory Cutaneous Scleroderma with Janus Kinase Inhibitors: A Systematic Review

Scleroderma is a connective tissue disorder characterized by hardening and thickening of the skin. Initial treatment involves topical and systemic corticosteroid therapies, with immunosuppressive therapy in severe and refractory cases, although none are curative and outcomes are often poor. This review evaluates the efficacy and safety of novel Janus Kinase inhibitors (JAKi) therapy use in cutaneous scleroderma refractory to conventional therapy.